Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines (Q28290236)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines	scientific article

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines (English)

0 references

0 references

10

object named as

David Dingli

0 references

Angela Dispenzieri

11

object named as

Angela Dispenzieri

0 references

2

object named as

Robert A Kyle

0 references

18

object named as

Martha Q Lacy

0 references

Stephen J. Russell

25

object named as

Stephen J Russell

0 references

S. Vincent Rajkumar

32

object named as

S Vincent Rajkumar

0 references

33

object named as

Morie A Gertz

0 references

Suzanne R Hayman

14

object named as

Suzanne R Hayman

0 references

Steven R Zeldenrust

30

object named as

Steven R Zeldenrust

0 references

19

object named as

John A Lust

0 references

Francis K Buadi

8

object named as

Francis K Buadi

0 references

17

object named as

Shaji K Kumar

0 references

Stephen M Ansell

1

object named as

Stephen M Ansell

0 references

Thomas E. Witzig

29

object named as

Thomas E Witzig

0 references

Grzegorz S Nowakowski

22

object named as

Grzegorz S Nowakowski

0 references

P Leif Bergsagel

7

object named as

P Leif Bergsagel

0 references

3

object named as

Craig B Reeder

0 references

24

object named as

Vivek Roy

0 references

5

object named as

Joseph R Mikhael

0 references

Philip R. Greipp

12

object named as

Philip R Greipp

0 references

Joseph P. Colgan

9

object named as

Joseph P Colgan

0 references

David J. Inwards-Breland

15

object named as

David J Inwards

0 references

Svetomir N Markovic

20

object named as

Svetomir N Markovic

0 references

Ivana N M Micallef

21

object named as

Ivana N M Micallef

0 references

23

object named as

Luis F Porrata

0 references

Kristen E Detweiler Short

26

object named as

Kristen E Detweiler Short

0 references

Carrie A Thompson

28

object named as

Carrie A Thompson

0 references

object named as

Rafael Fonseca

4

0 references

author name string

William G Morice

6

0 references

Thomas M Habermann

13

0 references

Patrick B Johnston

16

0 references

A Keith Stewart

27

0 references

Robert J Dalton

31

0 references

language of work or name

0 references

publication date

September 2010

0 references

0 references

85

0 references

824-33

0 references

9

0 references

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

Diagnosis and management of Waldenstrom's macroglobulinemia

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

6 April 2017

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

Myeloma and race: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

20 March 2017

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Asymptomatic Waldenstrom's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Treatment of Waldenström's macroglobulinemia with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Waldenström's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Waldenström's macroglobulinemia: clinical features, complications, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

29 September 2017

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

2 June 2018

Incidence of Waldenström's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

2 June 2018

The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

2 June 2018

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

International prognostic scoring system for Waldenstrom macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Extended rituximab therapy in Waldenström's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Fludarabine therapy in Waldenström's macroglobulinemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

patients with the description of a new scoring system and its validation on 253 other patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931618

27 November 2018

Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Waldenström macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasmapheresis in hyperviscosity syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Waldenström's macroglobulinemia: long-term results with the M-2 protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20702770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4065/MCP.2010.0304

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28290236&oldid=1902758367"